View More Recent Stories

May 12, 2022 04:15PM Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
May 3, 2022 04:08PM Aura Biosciences (AURA) Reports Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis
May 3, 2022 04:05PM Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
May 3, 2022 07:00AM Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
Mar 23, 2022 04:15PM Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
Mar 21, 2022 07:03AM Aura Biosciences (AURA) Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma
Mar 21, 2022 07:00AM Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
Mar 15, 2022 07:00AM Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
Mar 8, 2022 04:30PM Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
Feb 14, 2022 05:00PM Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
View More Recent Stories